Cargando…
Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
Autores principales: | Biolcati, G., Hanneken, S., Minder, E. I., Neumann, N. J., Wilson, J. H. P., Wolgen, P. J., Wright, D. J., Lloyd, A. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364892/ https://www.ncbi.nlm.nih.gov/pubmed/34396462 http://dx.doi.org/10.1186/s41687-021-00348-4 |
Ejemplares similares
-
Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
por: Biolcati, G., et al.
Publicado: (2021) -
Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2017) -
Erythropoietic protoporphyria
por: Lecha, Mario, et al.
Publicado: (2009) -
Microcytosis in Erythropoietic Protoporphyria
por: Graziadei, Giovanna, et al.
Publicado: (2022) -
Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)